This case highlights a potential association between the development of Brugada syndrome and underlying conduction system disturbances when exposed to class IC antiarrhythmics.
Class IC agents warrant ECG vigilance in conduction disease; leaves open true Brugada association versus drug effect.
We report a patient who first developed Brugada syndrome (BS) after the conduction in atrioventricular (AV) node and the ventricular conduction system was disturbed. A type-1 Brugada ECG was unexpectedly unmasked after administration of a class IC antiarrhythmic agent for suppressing paroxysmal atrial fibrillation (paf), which had never been documented in the absence of such conduction disturbances, even after giving antiarrhythmic agents for paf. In addition, this patient was accompanied by sick sinus syndrome. This was an intriguing overlap syndrome case in that the development of BS might have been associated with the incidence of a conduction system disturbance.
No takes yet. Share an insight, caveat, or question.
Hosokawa et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: